ADIL

Adial Pharmaceuticals Inc

May 15 • 04:00PM ET

1.38

+0.02 1.47 %

Healthcare • Biotechnology • USA • Nano • NASD

Index	-	P/E	-	EPS (ttm)	-9.90	Insider Own	1.44%	Shs Outstand	2.14M	Perf Week	-3.50%
Market Cap	2.96M	Forward P/E	-	EPS next Y	-2.49	Insider Trans	0.00%	Shs Float	2.11M	Perf Month	-14.81%
Enterprise Value	-1.62M	PEG	-	EPS next Q	-1.06	Inst Own	4.86%	Short Float	3.25%	Perf Quarter	-51.58%
Income	-7.77M	P/S	-	EPS this Y	55.91%	Inst Trans	1.24%	Short Ratio	0.60	Perf Half Y	-83.22%
Sales	0.00M	P/B	0.56	EPS next Y	52.66%	ROA	-179.08%	Short Interest	0.07M	Perf YTD	-74.91%
Book/sh	2.46	P/C	0.65	EPS next 5Y	47.67%	ROE	-265.94%	52W High	18.90 -92.70%	Perf Year	-91.64%
Cash/sh	2.14	P/FCF	-	EPS past 3/5Y	88.55% 53.46%	ROIC	-209.05%	52W Low	1.32 4.55%	Perf 3Y	-99.32%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.55% 5.73%	Perf 5Y	-99.91%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	75.60%	Oper. Margin	-	ATR (14)	0.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.18	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	29.72	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.18	EPS Q/Q	82.68%	SMA20	-8.79%	Beta	1.27	Target Price	25.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-16.34%	Rel Volume	0.62	Prev Close	1.36
Employees	6	LT Debt/Eq	0.00	Earnings	May 11 BMO	SMA200	-76.67%	Avg Volume	113.44K	Price	1.38
IPO	Jul 27, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	45.79% -	Trades		Volume	81,250	Change	1.47%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-14-24	Initiated	Rodman & Renshaw	Buy	$8
Oct-30-18	Initiated	Maxim Group	Buy	$5
Oct-11-18	Initiated	Dawson James	Buy

May-11-26 08:30AM	Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update (GlobeNewswire)
Apr-29-26 09:07AM	Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 (GlobeNewswire)
Apr-27-26 08:47AM	Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program (GlobeNewswire)
Apr-22-26 09:35AM	Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial (GlobeNewswire)
Mar-24-26 09:07AM	Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans (GlobeNewswire) -8.15%
08:00AM	Loading…
Mar-06-26 08:00AM	Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update (GlobeNewswire) -7.11%
Mar-03-26 08:17AM	Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement (GlobeNewswire) -7.29%
08:02AM	EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million (Benzinga)
Feb-24-26 09:00AM	Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement (GlobeNewswire)
Feb-23-26 08:30AM	Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One (GlobeNewswire)
Feb-17-26 09:00AM	Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire) -5.26%
Feb-04-26 09:35AM	Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04 (GlobeNewswire) -25.79%
Feb-03-26 04:05PM	Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement (GlobeNewswire)
Jan-14-26 09:00AM	Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045 (GlobeNewswire)
Jan-06-26 09:40AM	Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year? (Zacks)
08:00AM	Loading…
Nov-26-25 08:00AM	Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds (GlobeNewswire)
Nov-14-25 08:30AM	Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-17-25 09:00AM	Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show (GlobeNewswire)
Oct-09-25 08:30AM	Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution (GlobeNewswire)
Sep-30-25 09:42AM	CoreWeave initiated, Instacart downgraded: Wall Street's top analyst calls (The Fly) +6.35%
Sep-16-25 08:03AM	Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder (Benzinga)
08:00AM	Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04 (GlobeNewswire)
Sep-03-25 08:30AM	Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule (GlobeNewswire)
Sep-01-25 12:00PM	All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy (Zacks)
Aug-20-25 08:30AM	Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments (GlobeNewswire)
Aug-14-25 08:30AM	Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-06-25 08:00AM	Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting (GlobeNewswire)
Jul-16-25 08:30AM	Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement (GlobeNewswire) +10.05%
Jul-10-25 12:00PM	Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why (Zacks) +28.61%
Jul-09-25 08:30AM	Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045 (GlobeNewswire)
06:15AM	Loading…
06:15AM	Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck (GlobeNewswire)
Jun-25-25 08:30AM	Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply (GlobeNewswire) +7.28%
Jun-17-25 08:00AM	Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering (GlobeNewswire) -25.99%
Jun-16-25 08:00AM	Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting (GlobeNewswire) -7.14%
Jun-11-25 08:00AM	Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04 (GlobeNewswire) -23.77%
07:30AM	EXCLUSIVE: Adial Pharmaceuticals Lead Candidate For Alcohol Use Disorder Advances Toward Phase 3 Trial (Benzinga)
May-15-25 08:30AM	Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-13-25 08:30AM	Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study (GlobeNewswire)
May-08-25 08:30AM	Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration (GlobeNewswire)
08:02AM	EXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program (Benzinga)
May-02-25 11:48AM	Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds (GlobeNewswire) -14.10%
May-01-25 08:30AM	Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders (GlobeNewswire) +13.04%
08:02AM	EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent For Lead Drug For Alcohol And Opioid Use Disorders (Benzinga)
Mar-04-25 08:30AM	Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update (GlobeNewswire)
Feb-25-25 09:00AM	Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04 (GlobeNewswire) +20.64%
08:30AM	EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder (Benzinga)
Feb-19-25 09:00AM	Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies (GlobeNewswire)
Feb-12-25 09:00AM	Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders (GlobeNewswire)
08:30AM	EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders (Benzinga)
Jan-29-25 09:00AM	Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder (GlobeNewswire)
08:31AM	EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder (Benzinga)
Dec-03-24 08:30AM	Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations (GlobeNewswire)
08:00AM	EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations (Benzinga)
Nov-25-24 12:00PM	Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-14-24 08:30AM	Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder (GlobeNewswire) +15.04%
08:00AM	EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder (Benzinga)
Nov-13-24 08:30AM	Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 08:30AM	Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer (GlobeNewswire)
Oct-23-24 09:00AM	Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference (GlobeNewswire) -8.55%
Oct-17-24 09:00AM	Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company's Genetic Diagnostic for Addiction Treatment (GlobeNewswire) -5.82%
08:30AM	EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate (Benzinga)
Oct-15-24 09:00AM	Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery (GlobeNewswire)
Sep-19-24 08:30AM	Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder (GlobeNewswire)
Sep-04-24 09:00AM	Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-14-24 08:30AM	Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-13-24 09:00AM	Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04 (GlobeNewswire)
08:30AM	EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder (Benzinga)
Aug-07-24 09:00AM	Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder (GlobeNewswire)
08:30AM	EXCLUSIVE: Adial Pharmaceuticals' Last Patient Dosed in Pharmacokinetics Study of AD04 For Alcohol Use Disorder, Data Expected In Q4 (Benzinga)
Jul-31-24 08:30AM	Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044 (GlobeNewswire)
Jul-23-24 08:30AM	Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder (GlobeNewswire) +23.58%
08:00AM	EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder (Benzinga)
Jun-27-24 05:52AM	ADIL Stock Earnings: Adial Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
Jun-20-24 08:30AM	Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder (GlobeNewswire) -13.39%
08:00AM	EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For Alcohol Use Disorder (Benzinga)
Jun-06-24 07:00AM	MicroCap Rodeo's Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies (ACCESSWIRE)
Jun-05-24 03:17PM	Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025 (InvestorPlace)
08:30AM	Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder (GlobeNewswire)
08:00AM	EXCLUSIVE: Adial Pharmaceuticals Starts Patient Dosing In Pharmacokinetics Study Of AD04 For Alcohol Use Disorder (Benzinga)
May-29-24 08:30AM	Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th (GlobeNewswire)
May-15-24 09:54AM	ADIL Stock Earnings: Adial Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace)
08:30AM	Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-22-24 10:00AM	EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent (Benzinga)
08:30AM	Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office (GlobeNewswire)
Apr-10-24 11:53AM	Why Is Adial Pharmaceuticals (ADIL) Stock Up 59% Today? (InvestorPlace) +106.19%
08:30AM	Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder (GlobeNewswire)
Apr-02-24 08:30AM	Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update (GlobeNewswire)
Mar-01-24 07:00PM	Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds (GlobeNewswire) +59.80% -15.64%
Feb-28-24 09:30AM	Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office (GlobeNewswire) +85.50%
Feb-15-24 09:00AM	Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20 (ACCESSWIRE)
Feb-13-24 09:15AM	Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office (GlobeNewswire) +8.72%
Jan-18-24 08:30AM	Adial Announces Appointment of Tony Goodman as Chief Operating Officer (GlobeNewswire)
Dec-20-23 09:00AM	Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate (GlobeNewswire)
Nov-29-23 04:05PM	Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement (GlobeNewswire)
Nov-14-23 05:02PM	Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +7.46%
Oct-31-23 08:30AM	Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss New Aspects in Substance Use Treatment at The Annual International Society of Addiction Medicine Conference (GlobeNewswire)
Oct-30-23 12:00PM	All You Need to Know About Adial Pharmaceuticals, Inc. (ADIL) Rating Upgrade to Buy (Zacks)
Oct-25-23 08:00AM	Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar (GlobeNewswire)
Oct-24-23 04:30PM	Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Oct-20-23 08:00AM	Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -24.11%

Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. It offers the AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson and William B. Stilley, III in November 2010 and is headquartered in Glen Allen, VA.

CEOMr. Cary John Claiborne MBA

C.P.A.Mr. Vinay Shah A.C.A.

COO & DirectorMr. Tony Goodman

Chief Legal OfficerMr. John R. Martin J.D.

Vice President of Corporate DevelopmentMr. Andrew Taubman

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADIL

Adial Pharmaceuticals Inc

Upgrade your Finviz experience